In Vitro and In Silico Anti-Glioblastoma Activity of Hydroalcoholic Extracts of Artemisia annua L. and Artemisia vulgaris L.
-
Published:2024-05-23
Issue:11
Volume:29
Page:2460
-
ISSN:1420-3049
-
Container-title:Molecules
-
language:en
-
Short-container-title:Molecules
Author:
Bernatoniene Jurga12ORCID, Nemickaite Emilija1ORCID, Majiene Daiva13, Marksa Mindaugas4, Kopustinskiene Dalia M.2ORCID
Affiliation:
1. Department of Drug Technology and Social Pharmacy, Faculty of Pharmacy, Medical Academy, Lithuanian University of Health Sciences, Sukileliu pr. 13, LT-50161 Kaunas, Lithuania 2. Institute of Pharmaceutical Technologies, Faculty of Pharmacy, Medical Academy, Lithuanian University of Health Sciences, Sukileliu pr. 13, LT-50161 Kaunas, Lithuania 3. Laboratory of Biochemistry, Neuroscience Institute, Lithuanian University of Health Sciences, Eiveniu Street 4, LT-50162 Kaunas, Lithuania 4. Department of Analytical and Toxicological Chemistry, Medical Academy, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania
Abstract
Glioblastoma, the most aggressive and challenging brain tumor, is a key focus in neuro-oncology due to its rapid growth and poor prognosis. The C6 glioma cell line is often used as a glioblastoma model due to its close simulation of human glioma characteristics, including rapid expansion and invasiveness. Alongside, herbal medicine, particularly Artemisia spp., is gaining attention for its anticancer potential, offering mechanisms like apoptosis induction, cell cycle arrest, and the inhibition of angiogenesis. In this study, we optimized extraction conditions of polyphenols from Artemisia annua L. and Artemisia vulgaris L. herbs and investigated their anticancer effects in silico and in vitro. Molecular docking of the main phenolic compounds of A. annua and A. vulgaris and potential target proteins, including programmed cell death (apoptosis) pathway proteins proapoptotic Bax (PDB ID 6EB6), anti-apoptotic Bcl-2 (PDB ID G5M), and the necroptosis pathway protein (PDB ID 7MON), mixed lineage kinase domain-like protein (MLKL), in complex with receptor-interacting serine/threonine-protein kinase 3 (RIPK3), revealed the high probability of their interactions, highlighting the possible influence of chlorogenic acid in modulating necroptosis processes. The cell viability of rat C6 glioma cell line was assessed using a nuclear fluorescent double-staining assay with Hoechst 33342 and propidium iodide. The extracts from A. annua and A. vulgaris have demonstrated anticancer activity in the glioblastoma model, with the synergistic effects of their combined compounds surpassing the efficacy of any single compound. Our results suggest the potential of these extracts as a basis for developing more effective glioblastoma treatments, emphasizing the importance of further research into their mechanisms of action and therapeutic applications.
Reference66 articles.
1. Advances in glioblastoma multiforme: Integrating therapy and pathology perspectives;Shahcheraghi;Pathol. Res. Pract.,2024 2. Glioblastoma: Current Status, Emerging Targets, and Recent Advances;Thakur;J. Med. Chem.,2022 3. Leone, A., Colamaria, A., Fochi, N.P., Sacco, M., Landriscina, M., Parbonetti, G., de Notaris, M., Coppola, G., De Santis, E., and Giordano, G. (2022). Recurrent Glioblastoma Treatment: State of the Art and Future Perspectives in the Precision Medicine Era. Biomedicines, 10. 4. Rončević, A., Koruga, N., Soldo Koruga, A., Rončević, R., Rotim, T., Šimundić, T., Kretić, D., Perić, M., Turk, T., and Štimac, D. (2023). Personalized Treatment of Glioblastoma: Current State and Future Perspective. Biomedicines, 11. 5. Emerging therapies for glioblastoma: Current state and future directions;Rong;J. Exp. Clin. Cancer Res.,2022
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|